Roche Tamiflu “Re-Launch” Seeks To Bolster Seasonal Demand
This article was originally published in The Pink Sheet Daily
Executive Summary
Market research found that unprompted awareness of the antiviral was low, despite having strong publicity for use in pandemic preparedness.
You may also be interested in...
Tamiflu U.S. Labeling Adopts Japanese Warnings
Neuropsychiatric adverse event reports for Roche's antiviral jump in most recent review, prompting FDA staff to suggest a labeling change.
Tamiflu U.S. Labeling Adopts Japanese Warnings
Neuropsychiatric adverse event reports for Roche's antiviral jump in most recent review, prompting FDA staff to suggest a labeling change.
Tamiflu U.S. Labeling Adopts Japanese Warnings
A spike in the number of postmarketing adverse event reports associated with Tamiflu use is prompting FDA staff to recommend adoption of international labeling for the antiviral